ArticleFrontiers in medicine2025
Serological risk factors for steroid-induced osteonecrosis in HIV men: a Bayesian case-control study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human immunodeficiency virus (HIV)-infected individuals face diagnostic challenges for non-traumatic hormonal necrosis of femoral head (SONFH), as current imaging methods lack sensitivity/specificity and reliable biomarkers remain elusive. While coagulation disorders and dyslipidemia are known risk factors, evidence in HIV populations is limited. Methods: This case-control study enrolled 48 HIV-positive males with SONFH and 50 controls from Beijing Ditan Hospital (2021-2025). We analyzed demographic, coagulation, inflammatory, and metabolic markers. Random forest selected top 20 predictors, followed by Bayesian regression to assess associations (reported as OR, 95% CI, posterior probabilities, and Bayes factors). Results: Triglycerides (TG) showed the strongest SONFH association (OR = 85.911, 95% CI: 4.733-3078.857; BF = 82.048). Fibrinogen degradation products (FDP) (OR = 6.968, 95% CI: 1.485-51.347; BF = 6.692) and plasma thromboplastin antecedent (PTA) (OR = 2.890, 95% CI: 1.131-11.146; BF = 2.046) also demonstrated significant risk associations. Prolonged prothrombin time (PT) was protective (OR = 0.008, 95% CI: 0.0002-0.234; BF = 37.897). Conclusion: Elevated triglycerides, FDP, and PTA significantly increase the risk of SONFH in HIV patients, while prolonged PT may be protective. These serum markers could guide early intervention, though larger prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.